What I am working with: tirzepatide · three weeks.
I am at the decision point and I would rather think it through than improvise.
I would rather spend money on measurement than on redundancy.
What is the minimum version of this that is still defensible?
3 weeks is 21 days: 3 weekly administrations, and 0.75 four-week dose steps. Two draws fit inside that span honestly — baseline before the first dose, one repeat — plus a written trigger for anything extra. A third is a budget rather than a plan at 3 weeks. The constraint is that the markers worth drawing move more slowly than 21 days. An HbA1c integrates roughly the preceding ninety days, so a repeat at day 21 is still about 77 per cent pre-treatment blood and mostly reports where you started. Lipids and hepatic enzymes settle faster and are worth the repeat at 21 days. A renal panel earns its place at baseline specifically so that an early eGFR change has something to be a change from. Fix the repeat date at the start, in writing. A monitoring plan decided after a result arrives is not a plan, and nothing here is medical advice.
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
Stated carefully, delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe short version: a small, well-chosen panel with a baseline beats a large one without.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Keep the full report, not the number. You will need the units and the interval later.
This is answerable, and the answer is mostly about which tests rather than how many.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Decide the action for each result before you order the test.
edited 28 Apr 2026 by marta_okonkwo — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.